Rapidly Growing 'Pexclu'... Quarterly Sales Surpass 10 Billion Won

Published 24 Apr.2023 08:31(KST)

Daewoong Pharmaceutical's potassium-competitive acid blocker (P-CAB) mechanism gastroesophageal reflux disease treatment ‘Pexuclu’ (active ingredient: fexuprazan hydrochloride) continues to show strong performance.

Daewoong Pharmaceutical's gastroesophageal reflux disease treatment 'Pexuclu' <br>[Photo by Daewoong Pharmaceutical]

Daewoong Pharmaceutical's gastroesophageal reflux disease treatment 'Pexuclu'
[Photo by Daewoong Pharmaceutical]

On the 24th, Daewoong Pharmaceutical announced that according to pharmaceutical sample statistical information from Ubist, the prescription amount of Pexuclu in the first quarter (January to March) reached 10.8 billion KRW, an increase of about 31% compared to 8.3 billion KRW in the previous quarter. Compared to 4.6 billion KRW in the third quarter of last year, right after its launch, it increased by 136%.

Market share also rose significantly. Based on monthly prescription amounts, Pexuclu has ranked third among proton pump inhibitors (PPIs) and P-CAB treatments since February. It has steadily climbed from 11th place in its first month of launch.

Daewoong Pharmaceutical explained that these results are due to the advantages of Pexuclu. Pexuclu is a P-CAB drug that improves upon the shortcomings of existing PPI formulations by rapidly and stably suppressing gastric acid secretion. It offers benefits such as ▲fast onset of action ▲rapid and excellent symptom improvement ▲superior nighttime symptom relief ▲ease of administration ▲low drug interactions and consistent efficacy.

Daewoong Pharmaceutical plans to continue its momentum in the second quarter with strategic initiatives. First, it aims to complete entry into major tertiary hospitals within the first half of the year to steadily expand prescription channels, while continuously conducting academic marketing activities by hosting domestic and international symposiums and attending conferences and exhibitions. In particular, next month, it will open an offline promotional booth at the ‘2023 Digestive Disease Week (DDW)’?the world’s largest international gastroenterology conference held in Chicago, USA?to directly showcase the excellence of Pexuclu.

Park Eun-kyung, head of Daewoong Pharmaceutical’s ETC Marketing Division, stated, “We will continuously promote the strengths and excellence of Pexuclu both internally and externally and accelerate follow-up research for additional indications to grow it into a product with annual sales of 100 billion KRW. We will also pursue a global strategy to enter 100 countries by 2027.”